3:08 PM
 | 
Nov 13, 2017
 |  BC Extra  |  Company News

CRISPR, Casebia get rights to CureVac editing constructs

CureVac AG (Tuebingen, Germany) exclusively licensed Cas9 (CRISPR-associated protein 9) mRNA constructs to CRISPR Therapeutics AG (NASDAQ:CRSP) and its JV Casebia Therapeutics (Cambridge, Mass.) for use in three of their in vivo gene editing...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >